LGALS3 and neoplasm: In this study, those patients with high GAL‐3 tumor expression before treatment showed an early and dramatic progression after three cycles of treatment, and patients with negative or low/intermediate expression of GAL‐3 showed an early and durable objective responsiveness [69].